Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)

Bonnetain, F.; Bonsing, B.; Conroy, T.; Dousseau, A.; Glimelius, B.; Haustermans, K.; ... ; Collette, L. (2014)

Article / Letter to editor

• Pancreatic cancer
• Time to event end-point
• Consensus
• Guidelines
• Methodology
• Clinical trials

• All authors: Bonnetain, F.; Bonsing, B.; Conroy, T.; Dousseau, A.; Glimelius, B.; Haustermans, K.; Lacaine, F.; Laethem, J.L. van; Aparicio, T.; Aust, D.; Bassi, C.; Berger, V.; Chamorey, E.; Chibaudel, B.; Dahan, L.; Gramont, A. de; Delpero, J.R.; Dervenis, C.; Ducreux, M.; Gal, J.; Gerber, E.; Ghaneh, P.; Hammel, P.; Hendlisz, A.; Jooste, V.; Labianca, R.; Latouche, A.; Lutz, M.; Macarulla, T.; Malka, D.; Mauer, M.; Mitry, E.; Neoptolemos, J.; Pessaux, P.; Sauvanet, A.; Tabernero, J.; Taieb, J.; Tienhoven, G. van; Gourgou-Bourgade, S.; Bellera, C.; Mathoulin-Pelissier, S.; Collette, L.
• Date: 2014-11-30
• Journal: European Journal of Cancer
• Volume: 50
• Issue: 17
• Pages: 2983 - 2993
• DOI: doi:10.1016/j.ejca.2014.07.011